NAUT vs. TNYA, PACB, AKYA, BCAB, SEER, MESO, AFMD, QTRX, VBIV, and ORIC
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Tenaya Therapeutics (TNYA), Pacific Biosciences of California (PACB), Akoya Biosciences (AKYA), BioAtla (BCAB), Seer (SEER), Mesoblast (MESO), Affimed (AFMD), Quanterix (QTRX), VBI Vaccines (VBIV), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "medical" sector.
Tenaya Therapeutics (NASDAQ:TNYA) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Tenaya Therapeutics' return on equity of -22.42% beat Nautilus Biotechnology's return on equity.
Tenaya Therapeutics has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 33.8% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 42.5% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Tenaya Therapeutics had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Tenaya Therapeutics and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.33 beat Tenaya Therapeutics' score of 0.30 indicating that Tenaya Therapeutics is being referred to more favorably in the media.
Tenaya Therapeutics currently has a consensus target price of $15.40, suggesting a potential upside of 258.97%. Nautilus Biotechnology has a consensus target price of $6.00, suggesting a potential upside of 156.41%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, equities analysts plainly believe Tenaya Therapeutics is more favorable than Nautilus Biotechnology.
Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tenaya Therapeutics received 20 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 74.19% of users gave Tenaya Therapeutics an outperform vote while only 16.67% of users gave Nautilus Biotechnology an outperform vote.
Summary
Tenaya Therapeutics beats Nautilus Biotechnology on 10 of the 15 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
